the Accuracy and Safety of Coronary Artery Contrast-enhanced Magnetic Resonance Imaging With Polysaccharide Superparamagnetic Iron Oxide Nanoparticle

• Status: Not yet recruiting
• Trial end date: 2022-07-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a single-center, prospective, controlled and diagnostic clinical trial which will enroll 30 patients scheduled for coronary angiography in China.Patients will receive contrast-enhanced cardiac magnetic resonance with polysaccharide superparamagnetic iron oxide nanoparticle before percutaneous coronary angiography.In order to evaluate the safety of polysaccharide superparamagnetic iron oxide nanoparticle, patients will detect iron levels in peripheral and tissue before and after the examination.The main indicators of the study are the degree of coronary artery stenosis and the stability of coronary atherosclerotic plaque assessed by contrast-enhanced cardiac magnetic resonance with polysaccharide superparamagnetic iron oxide nanoparticle.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: The First Affiliated Hospital with Nanjing Medical University
• Collaborators: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.; School of Biomedical Engineering & Informatics, Nanjing Medical University; School of Bioscience & Medical Engineering, Southeast University

Criteria

Inclusion Criteria:

• Age ≧ 18 years, < 65 years;

• Patients who planned coronary angiography ;

• Patients with normal renal function or CKD stage 1-3;

• Patients themselves or authorized families to sign informed consent voluntarily.

Exclusion Criteria:

• Patients who were allergic to iodine contrast agent or had allergic history or allergic constitution to iron and dextran;

• Patients who can ' t accept magnetic resonance examination because of psychological ( such as autism syndrome ) or physical reasons ( such as metal retention in the body );

• Malignancies or other comorbid conditions with life expectancy less than 1 year;

• Pregnant or lactating woman;

• Hearing impaired persons;

• Cardiac function grade III-IV;

• History of coronary stenting or coronary artery bypass grafting;

• Patients who were taking other iron agents orally or intravenously;

• Patients with hemosiderin deposition or hemochromatosis;

• Patients with acute coronary syndromes;

• Any other patients that researcher deems it's unsuitable to be admitted.